The Hyunai Hope on Wheels nationwide campaign made a stop in Valhalla on September 26 at the Maria Fareri Children’s Hospital (MFCH) at Westchester Medical Center, to present NYMC with a $150,000 check and hold its signature handprint ceremony. NYMC was one of 40 recipients of the 2017 Hyundai Hope On Wheels Grants, which fund research projects with the greatest potential to improve the lives of children battling cancer.
The Hyundai Young Investigator Award is for the work of Allyson M. Flower, M.D., far left, assistant professor of pediatrics and a fellow in the Division of Pediatric Hematology, Oncology, and Stem Cell Transplantation, on neuroblastoma, one of the most common causes of cancer in childhood and one of the leading causes of cancer related deaths. Dr. Flower’s study, “Overcoming Natural Killer (NK) Cell Resistance in Poor Risk Neuroblastoma (NB),” aims to develop immunotherapeutic agents to overcome resistance pathways to eradicate neuroblastoma. View the Hyundai Hope On Wheels Ceremony photo gallery here.
On hand to commemorate the occasion were, from left: Edward C. Halperin, M.D., M.A., chancellor and chief executive officer; Mitchell Cairo, M.D., professor of pediatrics, medicine, pathology, microbiology and immunology and cell biology and anatomy, associate chairman of the Department of Pediatrics, chief of the Division of Pediatric Hematology, Oncology, and Stem Cell Transplantation, and director of the Children and Adolescent Cancer and Blood Diseases Center at MFCH, who serves as the mentor for the project; and Michael Gewitz, M.D., professor of pediatrics, vice chairman of the Department of Pediatrics and the William Russell McCurdy Physician-in-Chief of MFCH.
The handprint ceremony followed the check presentation, where children battling cancer at MFCH dipped their hands in paint and placed their handprints on the official Hyundai Hope Vehicle representing their individual and collective journeys, hopes and dreams. Launched in 1998, Hyundai Hope On Wheels has funded more than 840 research projects totaling more than $130 million for innovative treatments for childhood cancer.